Últimas noticias sobre VolitionRX (AMEX:VNRX) Bolsa

VolitionRX

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRX Ltd

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>VolitionRX</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/"><strong>VNRX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>VolitionRX reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company reported revenue of $395,797.</li><li>This was 17.54% worse than the analyst estimate for revenue of $480,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/vnrx-stock-earnings-volitionrx-for-q2-of-2024/">VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024

VolitionRX reports Q2 results

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Benchmark Co. analyst Bruce Jackson maintained a Hold rating on VolitionRX (VNRX – Research Report) today. The company's shares closed yesterday at...

Benchmark Co. Remains a Hold on VolitionRX (VNRX)

VolitionRX ( ($VNRX) ) has shared an announcement. Belgian Volition SRL has renewed its commitment to Dr. Gaetan Michel as CEO with a new employmen...

VolitionRX Confirms Dr. Michel's Leadership and Compensation Plan

VolitionRx files for common stock, warrants, and units for offering price of $1B

16:11 EST VolitionRx (VNRX) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...

VolitionRx files $100M mixed securities shelf

VolitionRX reports Q3 results

CEO Cameron Reynolds stated, "I am delighted that we have sold more than 110,000 Nu.Q Vet Cancer Tests in the first nine months of 2024; not only i...

VolitionRx reports Q3 revenue up 187% year-over-year to $475K

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

VNRX

Offerings

Press Releases

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

Volition Hosts KOL Roundtable on Sepsis

Volition Appoints Dr. Ethel Rubin as an Independent Director

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Small Cap

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Volition Appoints Timothy I. Still as Chairman

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Comments

VolitionRX

Noticias

Últimas noticias sobre VolitionRX (AMEX:VNRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL